Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9474824 | 0.87 | EPHX1 (0.47) | CHRNB2CHRNB4CHRNA4MMP2EPHX1 | |
| SCHEMBL4373918 | 0.85 | EPHX1 (0.52) | EPHX1SMN1; SMN2 | |
| SCHEMBL24977105 | 0.84 | EPHX1 (0.55) | EPHX1SMN1; SMN2 | |
| SCHEMBL9474469 | 0.84 | EPHX1 (0.55) | EPHX1SMN1; SMN2 | |
| SCHEMBL9854166 | 0.82 | KDM4E (0.46) | CHRNB2CHRNB4CHRNA4EPHX1MEN1 | |
| SCHEMBL3276345 | 0.81 | ALDH1A1 (0.41) | CHRNB2CHRNB4CHRNA4CHRNA3MMP1 | |
| SCHEMBL23269745 | 0.77 | NAMPT (0.38) | CHRNB2CHRNB4CHRNA4CHRNA3MMP1 | |
| SCHEMBL10809803 | 0.75 | MMP1 (0.39) | CHRNB2CHRNB4CHRNA4CHRNA3MMP1 | |
| SCHEMBL10809799 | 0.75 | MCL1 (0.37) | CHRNB2CHRNB4CHRNA4CHRNA3MMP1 | |
| SCHEMBL22559962 | 0.74 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140050779-A1 | TRANSGLUTAMINASE-2 INHIBITORS AND USES THEREOF | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2014-02-20 | — | — | US | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-20110065676-A1 | COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH NAR AGONISTS | SCHERING CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | CHRNB2 4505/4885CHRNB4 4618/4885CHRNA4 4612/4885 |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | CHRNB2 3658/4885CHRNB4 4342/4885CHRNA4 4348/4885 |
| US-20140050779-A1 | TRANSGLUTAMINASE-2 INHIBITORS AND USES THEREOF | TGM2, AGBL2, TGM3 | CHRNB2 3541/4885CHRNB4 4459/4885CHRNA4 4742/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | CHRNB2 4813/4885CHRNB4 4848/4885CHRNA4 4880/4885 |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | CHRNB2 4800/4885CHRNB4 4832/4885CHRNA4 4873/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | CHRNB2 4800/4885CHRNB4 4832/4885CHRNA4 4873/4885 |
| US-20110065676-A1 | COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH NAR AGONISTS | F2R, F2RL1, F2RL3 | CHRNB2 2282/4885CHRNB4 2261/4885CHRNA4 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.